Further, to improve efficacy and safety of FGF-21-based therapeutic strategies and with regard to a possible AT selective FGF-21 resistance in states of obesity, the development of tissue specific analogues has to be discussed. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.